Checkpoint Inhibitors market by Drug type (PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others) by Application (Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others), & by Region - Global Industry Analysis, Share, Size, Growth, Trends, and Forecasts (2016-2021)

Checkpoint Inhibitors market by Drug type (PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others) by Application (Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others), & by Region - Global Industry Analysis, Share, Size, Growth, Trends, and Forecasts (2016-2021)

ID: 2177 | Pages: 175 | May 2017 | Region: Global


Global Checkpoint Inhibitors Market was worth USD 6.08 billion in 2016 and is expected to reach USD 21.25 billion by 2021 with a CAGR of 28.4 %.

Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launches an attack when it detects infected or Cancerous. Immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on Cancer cells.

Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, high expense involved in R&D activities is one of the major factors restricting the growth of the market.

Checkpoint Inhibitors Market is segmented based on Drug type and Application. Based on Drug type, market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others. Based on Application, market is segmented into Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others. CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market to PD-1 inhibitors segment during the forecast period as majority of new treatments is based on PD-1 inhibitors.

Geographically, market is further segmented into Asia-Pacific, Europe, Latin America, Middle east and Africa and North America. North America dominates the global market owing the relatively high clinical trials and funding available in this region. Asia-Pacific is the fastest growing region because of collaborations of international players with companies in this region.

Some of the key players in the checkpoint inhibitors market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 PD-1 inhibitors       

                                5.1.3 PD-L1 inhibitors     

                                5.1.4 CTLA-4      

                                5.1.5  Chimeric Antigen Receptor T-cell 

                                5.1.6  Others     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type           

                                5.1.8 Market Attractiveness Analysis, By Drug Type         

                                5.1.9 Market Share Analysis, By Drug Type          

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Lung cancer            

                                5.2.3 Renal cancer           

                                5.2.4 Blood cancer          

                                5.2.5 Bladder Cancer      

                                5.2.6  Hodgkin lymphoma            

                                5.2.7 Melanoma              

                                5.2.8  Others     

                                5.2.9 Y-o-Y Growth Analysis, By Application         

                                5.2.10  Market Attractiveness Analysis, By Application   

                                5.2.11  Market Share Analysis, By Application     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                                6.1.3.3 By Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                                6.1.4.3 By Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Type

                                                6.1.5.3 By Application

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Merck & Co., Inc.                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 Roche                           

                8.4 AstraZeneca                               

                8.5 Ono Pharmaceutical Co., Ltd.                              

                8.6  Juno Therapeutics                  

                8.7 Novartis International AG                    

                8.8 Kite Pharma                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Global Checkpoint Inhibitors Market By Region, From 2016-2021 ( USD Million )
  2. Global Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  3. Global PD-1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  4. Global PD-L1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  5. Global CTLA-4 Market By Region, From 2016-2021 ( USD Million )
  6. Global Chimeric Antigen Receptor T-cell Market By Region, From 2016-2021 ( USD Million )
  7. Global Others Market By Region, From 2016-2021 ( USD Million )
  8. Global Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  9. Global Lung cancer Market By Region, From 2016-2021 ( USD Million )
  10. Global Renal cancer Market By Region, From 2016-2021 ( USD Million )
  11. Global Blood cancer Market By Region, From 2016-2021 ( USD Million )
  12. Global Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  13. Global Hodgkin lymphoma Market By Region, From 2016-2021 ( USD Million )
  14. Global Melanoma Market By Region, From 2016-2021 ( USD Million )
  15. Global Others Market By Region, From 2016-2021 ( USD Million )
  16. North America Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  17. North America PD-1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  18. North America PD-L1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  19. North America CTLA-4 Market By Region, From 2016-2021 ( USD Million )
  20. North America Chimeric Antigen Receptor T-cell Market By Region, From 2016-2021 ( USD Million )
  21. North America Others Market By Region, From 2016-2021 ( USD Million )
  22. North America Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  23. North America Lung cancer Market By Region, From 2016-2021 ( USD Million )
  24. North America Renal cancer Market By Region, From 2016-2021 ( USD Million )
  25. North America Blood cancer Market By Region, From 2016-2021 ( USD Million )
  26. North America Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  27. North America Hodgkin lymphoma Market By Region, From 2016-2021 ( USD Million )
  28. North America Melanoma Market By Region, From 2016-2021 ( USD Million )
  29. North America Others Market By Region, From 2016-2021 ( USD Million )
  30. United States Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  31. United States Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  32. Canada Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  33. Canada Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  34. Europe Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  35. Europe PD-1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  36. Europe PD-L1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  37. Europe CTLA-4 Market By Region, From 2016-2021 ( USD Million )
  38. Europe Chimeric Antigen Receptor T-cell Market By Region, From 2016-2021 ( USD Million )
  39. Europe Others Market By Region, From 2016-2021 ( USD Million )
  40. Europe Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  41. Europe Lung cancer Market By Region, From 2016-2021 ( USD Million )
  42. Europe Renal cancer Market By Region, From 2016-2021 ( USD Million )
  43. Europe Blood cancer Market By Region, From 2016-2021 ( USD Million )
  44. Europe Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  45. Europe Hodgkin lymphoma Market By Region, From 2016-2021 ( USD Million )
  46. Europe Melanoma Market By Region, From 2016-2021 ( USD Million )
  47. Europe Others Market By Region, From 2016-2021 ( USD Million )
  48. U.K. Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  49. U.K. Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  50. Germany Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  51. Germany Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  52. France Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  53. France Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  54. Italy Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  55. Italy Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  56. Spain Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  57. Spain Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  58. Asia-Pacific Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  59. Asia-Pacific PD-1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  60. Asia-Pacific PD-L1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  61. Asia-Pacific CTLA-4 Market By Region, From 2016-2021 ( USD Million )
  62. Asia-Pacific Chimeric Antigen Receptor T-cell Market By Region, From 2016-2021 ( USD Million )
  63. Asia-Pacific Others Market By Region, From 2016-2021 ( USD Million )
  64. Asia-Pacific Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  65. Asia-Pacific Lung cancer Market By Region, From 2016-2021 ( USD Million )
  66. Asia-Pacific Renal cancer Market By Region, From 2016-2021 ( USD Million )
  67. Asia-Pacific Blood cancer Market By Region, From 2016-2021 ( USD Million )
  68. Asia-Pacific Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  69. Asia-Pacific Hodgkin lymphoma Market By Region, From 2016-2021 ( USD Million )
  70. Asia-Pacific Melanoma Market By Region, From 2016-2021 ( USD Million )
  71. Asia-Pacific Others Market By Region, From 2016-2021 ( USD Million )
  72. Japan Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  73. Japan Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  74. China Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  75. China Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  76. India Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  77. India Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  78. Australia Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  79. Australia Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  80. South Korea Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  81. South Korea Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  82. Latin America Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  83. Latin America PD-1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  84. Latin America PD-L1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  85. Latin America CTLA-4 Market By Region, From 2016-2021 ( USD Million )
  86. Latin America Chimeric Antigen Receptor T-cell Market By Region, From 2016-2021 ( USD Million )
  87. Latin America Others Market By Region, From 2016-2021 ( USD Million )
  88. Latin America Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  89. Latin America Lung cancer Market By Region, From 2016-2021 ( USD Million )
  90. Latin America Renal cancer Market By Region, From 2016-2021 ( USD Million )
  91. Latin America Blood cancer Market By Region, From 2016-2021 ( USD Million )
  92. Latin America Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  93. Latin America Hodgkin lymphoma Market By Region, From 2016-2021 ( USD Million )
  94. Latin America Melanoma Market By Region, From 2016-2021 ( USD Million )
  95. Latin America Others Market By Region, From 2016-2021 ( USD Million )
  96. Brazil Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  97. Brazil Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  98. Argentina Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  99. Argentina Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  100. Mexico Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  101. Mexico Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  102. Rest of Latin America Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  103. Rest of Latin America Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  104. Middle East & Africa Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  105. Middle East & Africa PD-1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  106. Middle East & Africa PD-L1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  107. Middle East & Africa CTLA-4 Market By Region, From 2016-2021 ( USD Million )
  108. Middle East & Africa Chimeric Antigen Receptor T-cell Market By Region, From 2016-2021 ( USD Million )
  109. Middle East & Africa Others Market By Region, From 2016-2021 ( USD Million )
  110. Middle East & Africa Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  111. Middle East & Africa Lung cancer Market By Region, From 2016-2021 ( USD Million )
  112. Middle East & Africa Renal cancer Market By Region, From 2016-2021 ( USD Million )
  113. Middle East & Africa Blood cancer Market By Region, From 2016-2021 ( USD Million )
  114. Middle East & Africa Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  115. Middle East & Africa Hodgkin lymphoma Market By Region, From 2016-2021 ( USD Million )
  116. Middle East & Africa Melanoma Market By Region, From 2016-2021 ( USD Million )
  117. Middle East & Africa Others Market By Region, From 2016-2021 ( USD Million )
  118. Middle East Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  119. Middle East Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  120. Africa Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  121. Africa Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
Middle East And Africa Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Ov...
Latin America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive ...
Asia-pacific Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive B...
Europe Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder...
North America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive ...
Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder) And B...
Middle East And Africa Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Lab...
Latin-America Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories...
Asia-Pacific Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories,...
Europe Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories, Refer...
North-America Blood Culture Tests Market by Method (Automated, Manual), Product (Consumables, Instrument), Technology (Culture-based, PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospit...
Blood Culture Tests Market By Product Type (Gait Belts & Lift Vests, Canes, Crutches, Walker, Wheelchairs, Power Scooters), And Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018 To ...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.